(9 days)
Not Found
No
The device description and performance studies focus on the chemical properties and stability of glucose control solutions, with no mention of AI or ML technologies.
No
The device is a glucose control solution used to assess the performance of blood glucose meters and test strips, not to treat diabetes. It is for "in vitro diagnostic use."
Yes
Explanation: The "Intended Use / Indications for Use" states "For in vitro diagnostic use".
No
The device description clearly states it is a liquid control solution packaged in plastic bottles, indicating it is a physical product, not software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The "Intended Use / Indications for Use" section explicitly states "For in vitro diagnostic use".
- Device Description: The description details a liquid control solution used to assess the performance of meters and test strips, which are components of an in vitro diagnostic system for measuring glucose in blood.
- Predicate Device: The mention of a predicate device (K030703 TRUEcontrol Glucose Control Levels 0, 1, and 2) which is also a glucose control solution, further supports its classification as an IVD. Glucose control solutions are standard components used to verify the accuracy of glucose meters and test strips, which are IVD devices.
N/A
Intended Use / Indications for Use
The FDI Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TrueTrack®, TrackEASE® and TRUEread™ meters and test strips.
Product codes (comma separated list FDA assigned to the subject device)
JJX
Device Description
The FDI Glucose Controls consist of a viscosityadjusted, aqueous liquid control solutions containing known quantities of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
healthcare professionals and in the home by people with diabetes mellitus
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Tests were performed to verify specific performance characteristics:
-
- Accelerated and Real-time Stability
-
- Open Vial
-
- Test precision
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.1660 Quality control material (assayed and unassayed).
(a)
Identification. A quality control material (assayed and unassayed) for clinical chemistry is a device intended for medical purposes for use in a test system to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation. A quality control material (assayed and unassayed) may be used for proficiency testing in interlaboratory surveys. This generic type of device includes controls (assayed and unassayed) for blood gases, electrolytes, enzymes, multianalytes (all kinds), single (specified) analytes, or urinalysis controls.(b)
Classification. Class I (general controls). Except when intended for use in donor screening tests, quality control materials (assayed and unassayed) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
0
510(k) Premarket Notification: FDI Glucose Controls Fujirebio Diagnostics, Inc.
510(k) Summary 5
Introduction: According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.
Submitter:
Fujirebio Diagnostics, Inc. SEP 2 5 2009 940 Crossroads Blvd Seguin, TX 78155 (830) 372-1391 ex. 210 Establishment Registration Number: 1643621
Contact Person:
Device Name: FD! Glucose Controls Levels 1, 2. and 3
John C. Gormley
Common Name: Single Analyte Control Solution, All Types (Assayed and Unassayed)
Classification Name: Quality Control Material (assayed and unassayed).
Class I per 21 CFR 862.1660
Product Code:
Classification:
Panel:
Chemistry
75 JJX
Name:
Predicate Devices:
Manufacturer: 510(k) No.:
TRUEcontrol Glucose Control Levels 0, 1, and 2 Home Diagnostics, Inc. K030703
Device Description:
The FDI Glucose Controls consist of a viscosityadjusted, aqueous liquid control solutions containing known quantities of glucose. The product is packaged in plastic dropper tipped bottles for easy application of the control solutions to the test strips and a red coloration to aid the user to visually confirm application of the control. The product is nonhazardous and contains no human or animal derived materials.
Intended Use:
The FDI Glucose Controls are intended for in vitro diagnostic use (i.e. for external use only) by
1
510(k) Premarket Notification: FDI Glucose Controls Fujirebio Diagnostics, Inc.
healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TrueTrack®, TrackEASE® and TRUEread™ meters and test strips.
Comparison to Predicate Devices:
| Characteristic/
Aspect | Predicate Device | New Product |
---|---|---|
Name | TRUEcontrol Glucose Control | FDI Glucose Controls |
510(k), Date | K030703 | |
08/11/2003 | ||
Number of Levels | 3 | 3 |
Analyte | Glucose | Glucose |
Target Range | ||
(mg/dL) | 83 - 121(1) | 81 - 121(2) |
173 - 256(1) | 172 - 257(2) | |
341 - 516(1) | 328 - 490(2) | |
Container | Plastic bottle with dropper-tip | Plastic bottle with dropper-tip |
Fill Volume | 3.0 mL | 3.6 mL |
Color | Red | Red |
Matrix | Water, D-glucose, buffers, | |
viscosity enhancing agents, | ||
inorganic salts, amaranth, and | ||
preservatives. | Buffered aqueous solution of D- | |
Glucose, a viscosity modifier, | ||
preservatives, and other non- | ||
reactive ingredients | ||
Indications for Use | To check the performance the | |
TrueTrack®, TrackEASE® and | ||
TRUEreadTM meters and test | ||
strips | To check the performance of the | |
TrueTrack®, TrackEASE® and | ||
TRUEreadTM meters and test | ||
strips | ||
Target Population | Professional and home use | Professional and home use |
(1) Estimated from the manufacturer's published control ranges.
. .
(2)Based on a +/- 5% glucose concentration variability lot-to-lot and +/- 15% range
Performance Studies:
Tests were performed to verify specific performance characteristics:
-
- Accelerated and Real-time Stability
-
- Open Vial
-
- Test precision
Conclusion:
Comparison of the performance characteristics, formulation and intended use support the claim of substantial equivalence.
2
Image /page/2/Picture/0 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three stripes forming its body and wings. The eagle faces right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES : USA" is arranged in a circular fashion around the eagle.
DEPARTMENT OF HEALTH & HUMAN SERVICES
Fuirebio Diagnostics, Inc. c/o Mr. John C. Gormley Director of Quality & Regulatory Affairs 940 Crossroads Blvd. Seguin, TX 78155
SEP 2 5 2009
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
K092645 Re: Trade Name: FDI Glucose Controls Levels 1, 2 and 3 Regulation Number: 21 CFR §862.1660 Regulation Name: Ouality Control Material (assayed and unassayed). Regulatory Class: Class I, Reserved Product Codes: JJX Dated: August 25, 2009 Received: August 27, 2009
Dear Mr. Gormley:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
3
Page 2
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 796-5450. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (QSB's) Division of Postmarket Surveillance at (301) 796-5760. For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or ( 301 ) 796-5680 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
CA
Courtney C. Harper, Ph.D. Director Division of Chemistry and Toxicology Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
4
Indications for Use Statement 4 510(k) Number (if known): K092645
Device Name: FDI Glucose Controls
Indications for Use:
For in vitro diagnostic use (i.e. for external use only) by healthcare professionals and in the home by people with diabetes mellitus to assess the performance of the TrueTrack®, TrackEASE® and TRUEread™ meters and test strips.
Prescription Use X (21 CFR Part 801 Subpart D) AND/OR
Over-The-Counter Use . (21 CFR Part 807 Subpart C)
X
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)
Dision Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
K092645 510(k) -